医药魔方NextPharma & TrialCube数据库围绕行业现状及未来趋势,将早期临床研究与注册性临床研究的结果进行筛选,并对其中关键结果进行可视化呈现,以期赋能医药伙伴(可于文章后免费申请数据库试用)。 医药魔方数据库现建立“临研速递”专栏,定期发布精选的早期临床研究与注册性临床研究的可视化结果,敬请期待。 本期筛选的两...
1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)doi:10.1016/j.annonc.2024.08.1371N. ReinmuthL.G. Paz-Ares
representing over 60% of the trial population. This analysis was pre-specified in the protocol, but not alpha-controlled for formal statistical testing. This magnitude of difference was not observed in the sub-group of patients
1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung... N Reinmuth,LG Paz-Ares,MC Garassino,... - 《Annals of Oncology》 被引量: 0发表: 2024年 Sacituzumab govitecan (SG) + ...
随着生物科学技术的进步,各种类型创新疗法不断涌现并在临床研究得到验证,展现出了巨大的临床潜力。新技术、新靶点药物的早期临床研究与注册性临床研究(Pivotal Trial)的价值在整个药物研发中日益显著。其中,试验结果对于适应症拓展与后续研究的方案制定具有举足轻重的作用,因而对结果的解读很有必要。
Gilead plans to discuss results from this trial with regulators. The data will be presented at an upcoming medical meeting. “The totality of our data gives us continued confidence in Trodelvy’s potential in metastatic NSCLC, and in our broader lung cancer clinical development program,” said ...